Published: The New England Journal of Medicine
Date:
Authors: William V Tamborlane, Margarita Barrientos-Pérez, Udi Fainberg, Helle Frimer-Larsen, Mona Hafez, Paula M Hale, Muhammad Y Jalaludin, Margarita Kovarenko, Ingrid Libman, Jane L Lynch, Paturi Rao, Naim Shehadeh, Serap Turan, Daniel Weghuber, Timothy Barrett, Ellipse Trial Investigators
Abstract:
Metformin is the regulatory-approved treatment of choice for most youth with type 2 diabetes early in the disease. However, early loss of glycemic control has been observed with metformin monotherapy. Whether liraglutide added to metformin (with or without basal insulin treatment) is safe and effective in youth with type 2 diabetes is unknown.
Published: American Journal of Nephrology
Date:
Authors: Meg J Jardine 1 2 , Kenneth W Mahaffey 3 , Bruce Neal 1 4 5 6 , Rajiv Agarwal 7 , George L Bakris 8 , Barry M Brenner 9 , Scott Bull 10 , Christopher P Cannon 11 , David M Charytan 12 , Dick de Zeeuw 13 , Robert Edwards 10 , Tom Greene 14 , Hiddo J L Heerspink 13 , Adeera Levin 15 , Carol Pollock 16 , David C Wheeler 17 , John Xie 10 , Hong Zhang 18 , Bernard Zinman 19 , Mehul Desai 10 , Vlado Perkovic 1 , CREDENCE study investigators
Abstract:
People with diabetes and kidney disease have a high risk of cardiovascular events and progression of kidney disease. Sodium glucose co-transporter 2 inhibitors lower plasma glucose by reducing the uptake of filtered glucose in the kidney tubule, leading to increased urinary glucose excretion.
Published: The Lancet
Date:
Authors: NCD Risk Factor Collaboration (NCD-RisC)
Abstract:
Raised blood pressure is an important risk factor for cardiovascular diseases and chronic kidney disease. We estimated worldwide trends in mean systolic and mean diastolic blood pressure, and the prevalence of, and number of people with, raised blood pressure, defined as systolic blood pressure of 140 mm Hg or higher or diastolic blood pressure of 90 mm Hg or higher.
Published: The Lancet Diabetes & Endocrinology
Date:
Authors: NCD Risk Factor Collaboration (NCD-RisC)
Abstract:
Diabetes has been defined on the basis of different biomarkers, including fasting plasma glucose (FPG), 2-h plasma glucose in an oral glucose tolerance test (2hOGTT), and HbA1c. We assessed the effect of different diagnostic definitions on both the population prevalence of diabetes and the classification of previously undiagnosed individuals as having diabetes versus not having diabetes in a pooled analysis of data from population-based health examination surveys in different regions.
Published: The Lancet
Date:
Authors: Richard M Bergenstal 1, Carol Wysham, Leigh Macconell, Jaret Malloy, Brandon Walsh, Ping Yan, Ken Wilhelm, Jim Malone, Lisa E Porter, DURATION-2 Study Group
Abstract:
Most patients with type 2 diabetes begin pharmacotherapy with metformin, but eventually need additional treatment. We assessed the safety and efficacy of once weekly exenatide, a glucagon-like peptide 1 receptor agonist, versus maximum approved doses of the dipeptidyl peptidase-4 inhibitor, sitagliptin, or the thiazolidinedione, pioglitazone, in patients treated with metformin.
Published: Am J Clin Nutr
Date:
Authors: Matthew J Delmonico 1 , Tamara B Harris, Marjolein Visser, Seok Won Park, Molly B Conroy, Pedro Velasquez-Mieyer, Robert Boudreau, Todd M Manini, Michael Nevitt, Anne B Newman, Bret H Goodpaster, Health, Aging, and Body
Abstract:
Sarcopenia is thought to be accompanied by increased muscle fat infiltration. However, no longitudinal studies have examined concomitant changes in muscle mass, strength, or fat infiltration in older adults.
Published: Expert Opin Pharmacother
Date:
Authors: Pedro A Velásquez-Mieyer 1 , Claudia P Neira
Abstract:
Type 1 diabetes mellitus is associated with acute and long-term complications, to which pre- and postprandial hyperglycemia are independent contributors. The objective of this review was to evaluate evidence-based information using biphasic insulin aspart 30 in the treatment of type 1 diabetes mellitus.
Published: Clinical Pharmacology & Therapeutics
Date:
Authors: J A Batsis 1 , R E Nieto-Martinez, F Lopez-Jimenez
Abstract:
The metabolic syndrome (MetS) encompasses a constellation of metabolic abnormalities that are thought to place patients at higher risk for the development of diabetes and cardiovascular (CV) disease.
Published: Therapeutic Advances in Cardiovascular Disease
Date:
Authors: Pedro Velasquez-Mieyer 1 , Claudia P Neira, Ramfis Nieto, Patricia A Cowan
Abstract:
The cardiometabolic syndrome is highly prevalent among overweight youth. The risk of developing the cardiometabolic syndrome is likely triggered or exacerbated by concurrent obesity, unhealthy lifestyle/eating habits, and hormonal changes (puberty).